Association of interleukin-36α and interleukin-38 with type 2 diabetes mellitus and diabetic neuropathy

The Egyptian Journal of Internal Medicine

Table 1 Clinical, demographic, and laboratory data for type 2 diabetes mellitus patients without and with diabetic neuropathy

Data; median (IQR)	T2D; n = 85	DNP; n = 21	p-value
Age; year	52 (47–60)	59 (52–67)	0.04
Age at onset; year	45 (40–51)	49 (43–55)	0.243
Disease duration; year	6 (3–10)	10 (7–15)	0.05
BMI; kg/m²	31.2 (28.1–36.3)	30.5 (26.6–37.5)	0.632
WHR	0.95 (0.90–0.98)	0.94 (0.91–1.04)	0.414
FPG; mg/dL	180 (127–250)	180 (155–279)	0.5
HbA1c; %	8.5 (7.4–10.1)	8.4 (7.7–10.5)	0.503
ALT; U/L	15 (10–23)	11 (10–24)	0.272
AST; U/l	23 (16–29)	25 (18–26)	0.557
ALP; IU/L	89 (65–134)	90 (65–135)	0.89
TC; mg/dL	183 (148–222)	184 (165–229)	0.419
TG; mg/dL	130 (89–191)	154 (110–194)	0.911
HDL; mg/dL	39 (25–53)	47 (38–57)	0.222
LDL; mg/dL	120 (76–159)	119 (88–122)	0.695

IQR interquartile range, BMI body mass index, WHR waist-to-hip ratio, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase; TC, total cholesterol, TG triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, T2D type 2 diabetes mellitus patients without diabetic neuropathy, DNP, type 2 diabetes mellitus patients with diabetic neuropathy; p, two-tailed probability (significance was assessed using Mann-Whitney U-test; significant p-value is indicated in bold)